Conjugated To A Detectable Label Or Radioisotope Or Radionuclide Or Heavy Metal-containing Compound Patents (Class 530/391.3)
-
Publication number: 20140050757Abstract: The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.Type: ApplicationFiled: November 1, 2013Publication date: February 20, 2014Applicant: IDEXX LABORATORIES, INC.Inventors: Jiayou Liu, Eugene Regis Krah, III, Thomas Patrick O'Connor, JR., Daniel Karl Rieger
-
Publication number: 20140051145Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: ApplicationFiled: October 26, 2012Publication date: February 20, 2014Applicant: Agensys, Inc.Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Publication number: 20140051084Abstract: The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).Type: ApplicationFiled: November 28, 2011Publication date: February 20, 2014Inventors: Tormod Fladby, Lisbeth Johnsen, Hanne Mali Mollergard
-
Publication number: 20140051840Abstract: The present invention provides radioactive arsenic complex useful in diagnostic and therapeutic applications and methods for forming those arsenic complexes.Type: ApplicationFiled: August 16, 2013Publication date: February 20, 2014Inventors: Silvia S. Jurisson, Cathy S. Cutler, Donald E. Wycoff, Anthony J. DeGraffenreid
-
Publication number: 20140044739Abstract: The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.Type: ApplicationFiled: February 8, 2013Publication date: February 13, 2014Inventors: Nelson N. H. Teng, Neelima M. Bhat, Marcia M. Bieber, Bruce A. Keyt
-
Publication number: 20140044723Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.Type: ApplicationFiled: July 24, 2013Publication date: February 13, 2014Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
-
Publication number: 20140044714Abstract: Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.Type: ApplicationFiled: April 19, 2012Publication date: February 13, 2014Inventors: Mitchell Ho, Mingqian Feng, Wei Gao, Heungnam Kim, Dimiter S. Dimitrov
-
Publication number: 20140044738Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.Type: ApplicationFiled: April 19, 2012Publication date: February 13, 2014Applicant: AMPLIMMUNE, INC.Inventors: Solomon Langermann, Linda Liu, Shannon Marshall, Sheng Yao
-
Patent number: 8648172Abstract: The present invention provides antibodies that simultaneously bind the ?- and ?-subunits of an intact MUC1 protein, and methods for making and using such antibodies.Type: GrantFiled: November 16, 2011Date of Patent: February 11, 2014Assignees: Biomodifying, LLC, Ramot at Tel Aviv University Ltd.Inventors: Daniel B. Rubinstein, Daniel H. Wreschner
-
Patent number: 8648174Abstract: The present invention is directed to novel polypeptide, designated in the present application as “UCP4” (SEQ ID NO: 1), having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: November 8, 2012Date of Patent: February 11, 2014Assignee: Genentech, Inc.Inventors: Sean Adams, James Pan, Alan Zhong
-
Publication number: 20140039166Abstract: A silica nanoparticle for diagnostic imaging that may be capable of use for X-ray CT, fluorescent imaging, or the like, and have high emission intensity. A method for producing such a silica nanoparticle for diagnostic imaging is provided. Also, a biosubstance labeling agent using the silica nanoparticle for diagnostic imaging is provided. The silica nanoparticle for diagnostic imaging encapsulates an organic fluorescent dye and a metal complex, wherein a ligand of the metal complex form a covalent bond with constituent molecules of the silica nanoparticle.Type: ApplicationFiled: March 15, 2012Publication date: February 6, 2014Applicant: KONICA MINOLTA, INC.Inventors: Takuji Aimiya, Naoko Furusawa, Yasushi Nakano
-
Publication number: 20140037636Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: ApplicationFiled: July 12, 2013Publication date: February 6, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Tomoyuki TAHARA, Yoshikatsu KANAI, Hitoshi ENDOU, Shiro KATAOKA, Kazumasa HASEGAWA, Tetsuya YOSHINO
-
Publication number: 20140037540Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: October 14, 2013Publication date: February 6, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: DEBBIE LAW, KURT GISH
-
Publication number: 20140023662Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: October 28, 2011Publication date: January 23, 2014Applicant: ImmunoGen, Inc.Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Publication number: 20140023649Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 15, 2013Publication date: January 23, 2014Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Publication number: 20140017679Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.Type: ApplicationFiled: April 17, 2013Publication date: January 16, 2014Applicant: BioNTech AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
-
Publication number: 20140017807Abstract: The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) wherein R1, R2 and R2* each independently are selected from carbon-containing substituents forming a C—O bond with the neighbouring oxygen atom, R3 and R4 each represent a bond between the chromophoric moiety and other moieties of the chelate, and Ln3+ is a lanthanide ion, as well as the corresponding luminescence lanthanide chelating ligand. The application also discloses a detectable molecule comprising a biospecific binding reactant (such as an antibody) conjugated to the luminescent lanthanide chelate as well as a method of carrying out a biospecific binding assay, the use of such a detectable molecule in a specific bioaffinity based binding assay utilizing time-resolved fluorometric determination of a specific luminescence, and a solid support material conjugated with the luminescent lanthanide chelate.Type: ApplicationFiled: December 21, 2012Publication date: January 16, 2014Applicant: DHR Finland OYInventors: Niko Meltola, Harri Takalo, Henri Sund
-
Patent number: 8629247Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.Type: GrantFiled: April 14, 2010Date of Patent: January 14, 2014Assignee: Proscan RX Pharma Inc.Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Patent number: 8628749Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.Type: GrantFiled: January 28, 2011Date of Patent: January 14, 2014Assignee: Nordic Nanovector ASInventors: Roy H. Larsen, Jostein Dahle, Øyvind S Bruland
-
Publication number: 20140010814Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein: (i) the Fc region comprises two non-identical heavy chains, wherein at least one of the two non-identical heavy chains comprises an amino acid modification so as to form complementation between the two non-identical heavy chains thereby increasing the probability of forming heterodimers of the non-identical heavy chains and decreasing the probability of forming homodimers of identical heavy chains; and (ii) the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain.Type: ApplicationFiled: March 15, 2012Publication date: January 9, 2014Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Itai Benhar, Lilach Vaks
-
Publication number: 20140010811Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang, Thomas P. Conrads, Elvira Favoino, Brian L. Hood
-
Publication number: 20140010816Abstract: The present invention relates to polypeptides from Plasmodium and polynucleotides encoding the polypeptides. The invention further relates to compositions comprising the polypeptides and their use in the treatment and prevention of malaria.Type: ApplicationFiled: November 8, 2011Publication date: January 9, 2014Inventors: Lin Chen, Alan Cowman, Tony Triglia
-
Publication number: 20140010829Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: ApplicationFiled: November 15, 2011Publication date: January 9, 2014Applicants: The Gov't of the United States, as Represented by, The Secretary of Health and Human Services, DUKE UNIVERSITYInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Publication number: 20140011208Abstract: The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.Type: ApplicationFiled: April 9, 2013Publication date: January 9, 2014Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Ching-Ying Cheung
-
Patent number: 8623324Abstract: Chemically reactive dyes that are intramolecularly crosslinked with a water-soluble bridge, their bioconjugates and their uses are described. Reactive fluorescent dyes that have a water-soluble bridge are superior to those of conjugates of spectrally non-crosslinked dyes or the dyes that are crosslinked with a hydrophobic bridge. The invention includes reactive fluorescent dyes, their biological conjugates and uses.Type: GrantFiled: July 12, 2011Date of Patent: January 7, 2014Assignees: AAT Bioquest Inc., Becton, Dickinson and CompanyInventors: Timothy Dubrovsky, Barnaby Abrams, Zhenjun Diwu, Qinglin Meng, Jinfang Liao, Haitao Guo
-
Patent number: 8624001Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD 19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hAl9 VH sequence.Type: GrantFiled: June 17, 2013Date of Patent: January 7, 2014Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20140004037Abstract: The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.Type: ApplicationFiled: January 19, 2012Publication date: January 2, 2014Applicant: Therapeutic Proteins, Inc.Inventor: Rosemarie Wilton
-
Publication number: 20140004536Abstract: To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.Type: ApplicationFiled: May 10, 2013Publication date: January 2, 2014Applicants: PERSEUS PROTEOMICS INC., FUJITA HEALTH UNIVERSITYInventors: Yoshikazu KUROSAWA, Maiko KUROSAWA, Gene KUROSAWA
-
Publication number: 20140004542Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.Type: ApplicationFiled: May 10, 2012Publication date: January 2, 2014Applicant: BIOCARE MEDICAL, LLCInventors: Weimin Qi, David Tacha
-
Patent number: 8618265Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.Type: GrantFiled: March 2, 2010Date of Patent: December 31, 2013Assignee: Ventana Medical Systems, Inc.Inventors: Jerome W. Kosmeder, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
-
Publication number: 20130344075Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: ApplicationFiled: June 6, 2011Publication date: December 26, 2013Applicant: VASGENE THERAPEUTICS, INC.Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
-
Publication number: 20130344071Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: May 21, 2013Publication date: December 26, 2013Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20130344076Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: ApplicationFiled: March 26, 2013Publication date: December 26, 2013Applicant: Viventia Bio Inc.Inventors: Francina C. CHAHAL, Jeannick CIZEAU
-
Publication number: 20130344078Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.Type: ApplicationFiled: August 21, 2013Publication date: December 26, 2013Applicant: The Regents of The University of CaliforniaInventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
-
Publication number: 20130344497Abstract: Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer.Type: ApplicationFiled: September 4, 2013Publication date: December 26, 2013Applicant: Duke UniversityInventors: Murat O. Arcasoy, Zishan A. Haroon
-
Publication number: 20130345406Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).Type: ApplicationFiled: June 7, 2013Publication date: December 26, 2013Applicant: GENMAB A/SInventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
-
Publication number: 20130336995Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: August 21, 2013Publication date: December 19, 2013Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga
-
Publication number: 20130336975Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne McNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20130336885Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 29, 2013Publication date: December 19, 2013Applicant: GENENTECH INC.Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
-
Publication number: 20130337533Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.Type: ApplicationFiled: June 28, 2013Publication date: December 19, 2013Inventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
-
Publication number: 20130340102Abstract: Provided herein are humanized forms of murine RP215 monoclonal antibodies and methods of using the same. These humanized RP215 monoclonal antibodies were characterized in terms of their respective affinity and specificity to the corresponding tumor-associated antigen, CA215, and shown to be comparable to those of murine RP215.Type: ApplicationFiled: March 12, 2013Publication date: December 19, 2013Inventor: Gregory LEE
-
Publication number: 20130337536Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.Type: ApplicationFiled: August 21, 2013Publication date: December 19, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Evan Antoulinakis, Kyle Gee, Aleksey Rukavishnikov
-
Patent number: 8609096Abstract: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.Type: GrantFiled: February 4, 2013Date of Patent: December 17, 2013Assignee: Alper Biotech, LLCInventor: Özge Alper
-
Publication number: 20130330347Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: January 25, 2013Publication date: December 12, 2013Applicants: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KGInventors: ABBVIE DEUTSCHLAND GMBH & CO. KG, AbbVie Inc.
-
Publication number: 20130330359Abstract: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.Type: ApplicationFiled: December 13, 2012Publication date: December 12, 2013Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
-
Publication number: 20130330279Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.Type: ApplicationFiled: December 22, 2012Publication date: December 12, 2013Applicant: NNANOAXIS, LLCInventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
-
Publication number: 20130330343Abstract: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.Type: ApplicationFiled: December 13, 2012Publication date: December 12, 2013Applicants: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
-
Publication number: 20130330742Abstract: The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. The novel antigen disclosed is a 60,000 Dalton glycoprotein found on the cell surface of human tumor cells.Type: ApplicationFiled: December 1, 2010Publication date: December 12, 2013Applicant: EDP Biotech CorporationInventor: Tommye Jordan
-
Publication number: 20130330344Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: August 22, 2013Publication date: December 12, 2013Applicant: UCB PHARMA S.A.Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG
-
Publication number: 20130330330Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: ApplicationFiled: July 30, 2013Publication date: December 12, 2013Applicant: ZYMOGENETICS, INC.Inventors: Wenfeng XU, Wayne R. KINDSVOGEL, Steven D. HUGHES, Yasmin A. CHANDRASEKHER